Private sector opportunities and threats to achieving malaria elimination in the Greater Mekong Subregion: results from malaria outlet surveys in Cambodia, the Lao PDR, Myanmar, and Thailand

Abstract

BackgroundThe aim of this paper is to review multi-country evidence of private sector adherence to national regulations, guidelines, and quality-assurance standards for malaria case management and to document current coverage of private sector engagement and support through ACTwatch outlet surveys implemented in 2015 and 2016.ResultsOver 76,168 outlets were screened, and approximately 6500 interviews were conducted (Cambodia, N = 1303; the Lao People’s Democratic Republic (PDR), N = 724; Myanmar, N = 4395; and Thailand, N = 74). There was diversity in the types of private sector outlets providing malaria treatment across countries, and the extent to which they were authorized to test and treat for malaria differed. Among outlets stocking at least one anti-malarial, public sector availability of the first-line treatment for uncomplicated Plasmodium falciparum or Plasmodium vivax malaria was >75%. In the anti-malarial stocking private sector, first-line treatment availability was variable (Cambodia, 70.9%; the Lao PDR, 40.8%; Myanmar P. falciparum = 42.7%, P. vivax = 19.6%; Thailand P. falciparum = 19.6%, P. vivax = 73.3%), as was availability of second-line treatment (the Lao PDR, 74.9%; Thailand, 39.1%; Myanmar, 19.8%; and Cambodia, 0.7%). Treatment not in the National Treatment Guidelines (NTGs) was most common in Myanmar (35.8%) and Cambodia (34.0%), and was typically stocked by the informal sector. The majority of anti-malarials distributed in Cambodia and Myanmar were first-line P. falciparum or P. vivax treatments (90.3% and 77.1%, respectively), however, 8.8% of the market share in Cambodia was treatment not in the NTGs (namely chloroquine) and 17.6% in Myanmar (namely oral artemisinin monotherapy). In the Lao PDR, approximately 9 in 10 anti-malarials distributed in the private sector were second-line treatments—typically locally manufactured chloroquine. In Cambodia, 90% of anti-malarials were distributed through outlets that had confirmatory testing available. Over half of all anti-malarial distribution was by outlets that did not have confirmatory testing available in the Lao PDR (54%) and Myanmar (59%). Availability of quality-assured rapid diagnostic tests (RDT) amongst the RDT-stocking public sector ranged from 99.3% in the Lao PDR to 80.1% in Cambodia. In Cambodia, the Lao PDR, and Myanmar, less than 50% of the private sector reportedly received engagement (access to subsidized commodities, supervision, training or caseload reporting), which was most common among private health facilities and pharmacies.ConclusionsFindings from this multi-country study suggest that Cambodia, the Lao PDR, Myanmar, and Thailand are generally in alignment with national regulations, treatment guidelines, and quality-assurance standards. However, important gaps persist in the private sector which pose a threat to national malaria control and elimination goals. Several options are discussed to help align the private sector anti-malarial market with national elimination strategies.Electronic supplementary materialThe online...

Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries

“…A survey of antimalarial availability and use among physicians, pharmacists, and patients across 6 states in India in 2008 found primaquine was prescribed for confirmed vivax malaria in 87% of patients in the public sector and 52% in the private sector [ 36 ]. In most other countries, very little primaquine is prescribed from the private sector, yet in many countries, this is the main source of antimalarials (Lao PDR [ 37 ], Cambodia, and Myanmar [ 38 ]).…”

“…While G6PD deficiency testing is recommended officially [ 47 ] in many countries, in reality, it is not available at point of care, leaving prescribers to make their own decisions. Apart from the Indian subcontinent, there is very little use of primaquine in the private sector [ 37 , 38 ], which in many countries is the main source of antimalarial treatment. Reported adherence to unobserved 14-day radical cure regimens varies between different studies (adherence was considered poor in Papua Indonesia [ 48 ], where most patients are children; in 2 studies in Thailand [ 49 , 50 ]; and in studies from India, but good in other studies in Pakistan [an Afghan refugee camp] [ 51 ], Brazil [ 52 ], and the Thailand-Myanmar border [ 53 ]).…”

Expanding malaria diagnosis and treatment in Lao PDR: lessons learned from a public–private mix initiative

“…Data from an ACTwatch outlet survey conducted from November to December 2015 were also referenced. Details about the ACTwatch project and methodology have been published elsewhere [ 12 ]. The ACTwatch 2015 survey was conducted in 41 districts [ 13 ] in the southern five provinces (Attapeu, Champasak, Salavanh, Savannaket, Sekong) of which 25 districts were part of the PPM programme.…”

When it just won’t go away: oral artemisinin monotherapy in Nigeria, threatening lives, threatening progress

“…Previous ACTwatch outlet surveys suggest that availability of oral AMT in Nigeria was in decline prior to 2015. In 2009, nearly half of all anti-malarial-stocking private sector outlets had oral AMT in stock (46%), and availability declined to 35% in 2011 and 25% in 2013 [ 4 ]. A continued decline in availability would be expected given the ban on oral AMT in place for several years prior to the 2015 survey [ 19 ].…”

“…The loss of ACT efficacy would be disastrous for malaria endemic countries and would severely impede global malaria control and elimination progress [ 1 ]. Results from ACTwatch outlet surveys have shown that within a few years of the WHO recommendation, oral AMT was no longer available to consumers in multiple malaria endemic countries [ 3 , 4 ]. The exception is ongoing availability and distribution in Nigeria, as described further in this paper, as well as in Myanmar, where oral AMT continues to be available and distributed despite the country’s national policy which has banned the use and importation of this anti-malarial [ 5 – 7 ].…”